BOEHRINGER INGELHEIM VIRAMUNE FOR COMBINATION USE WILL BE ON THE MARKET BY END OF JULY; INTERACTION STUDIES WITH PROTEASE INHIBITORS PART OF PHASE IV
Executive Summary
Boehringer Ingelheim plans to launch Viramune (nevirapine) by late July, the company said following FDA's June 21 accelerated approval of the HIV treatment.